CPT code 87485 represents a molecular diagnostic assay using a direct nucleic acid probe to detect Chlamydia pneumoniae, an agent of respiratory infections that ranges from mild illness in children to more severe disease in adults. This code is used by clinical and hospital laboratories to report the testing procedure when direct probe techniques are employed. Nationally, accurate reporting of such pathogen-specific molecular tests supports surveillance, appropriate clinical management, and lab payment consistency.

Key payers covered in this discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code denotes, the typical laboratory and clinical context in which it is used, and the expected sites of service. The publication also describes benchmarks and policy-relevant topics readers can expect, including billing and coding considerations for molecular infectious disease testing, payer coverage patterns, and clinical implications of identifying Chlamydia pneumoniae in respiratory specimens.

Data not available in the input for payer-specific rates, claim volumes, associated taxonomies, and ICD-10 diagnoses. The report focuses on clinical context, coding definition, and national relevance of CPT code 87485.